Design, Synthesis and Characterization of 5-(2-Bromo-5-Fluorophenyl)-3-(1h-Pyrrol-2-Yl)-4,5-Dihydro-1h-Pyrazole as Antifungal Agent

  • Chandra Shekhar Yadav
  • Atul Krishna
  • Vijay Kumar Verma
  • Zaheeb Rashid Wani
  • Iqbal Azad
  • Abdul Rahman Khan
  • Minaxi B. Lohani
Keywords: Synthesis, ADMET, Drug-likeness, Antifungal, Characterization

Abstract

This study successfully synthesized a novel compound (5-(2-bromo-5-fluorophenyl)-3-(1H-pyrrol-2-yl)-4,5-dihydro-1H-pyrazole (6), from an α, β-unsaturated carbonyl compound (5). The compound was characterized using various spectroscopic techniques, including 1???? NMR, 13???? NMR, and mass spectrometry. Its antifungal potential was evaluated against three fungal strains including Candida tropicalis, Candida parapsilosis, and Candida albicans. The results indicated that compound (6) exhibited moderate antifungal activity. Furthermore, molecular descriptors and ADMET profiling were employed in an in-silico simulation to assess the compound's drug-likeness. This study thus presents a valuable strategy for developing more effective antifungal agents.

Author Biographies

Chandra Shekhar Yadav

Department of Chemistry, Integral University, Lucknow, India

Atul Krishna

Division of Molecular Microbiology and Immunology, CSIR-CDRI, Lucknow, India

Vijay Kumar Verma

Department of Laboratory Animal Facility, CSIR-CDRI, Lucknow, India

Zaheeb Rashid Wani

Department of Laboratory Animal Facility, CSIR-CDRI, Lucknow, India

Iqbal Azad

Department of Chemistry, Integral University, Lucknow, India

Abdul Rahman Khan

Department of Chemistry, Integral University, Lucknow, India

Minaxi B. Lohani

Department of Chemistry, Integral University, Lucknow, India

References

[1] J. R. Rees, R. W. Pinner, R. A. Hajjeh, M. E. Brandt, and A. L. Reingold, “The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillance,” academic.oup.comJR Rees, RW Pinner, RA Hajjeh, ME Brandt, AL ReingoldClinical Infectious Diseases, 1998•academic.oup.com, Accessed: Oct. 08, 2024. [Online]. Available: https://academic.oup.com/cid/article-abstract/27/5/1138/480369
[2] J. Fostel, P. L.-D. discovery today, and undefined 2000, “Emerging novel antifungal agents,” ElsevierJM Fostel, PA LarteyDrug discovery today, 2000•Elsevier, Accessed: Oct. 08, 2024. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S1359644699014300
[3] M. Henary, C. Kananda, L. Rotolo, B. Savino, E. A. Owens, and G. Cravotto, “Benefits and applications of microwave-assisted synthesis of nitrogen containing heterocycles in medicinal chemistry,” RSC Advances, vol. 10, no. 24, pp. 14170–14197, Apr. 2020, doi: 10.1039/D0RA01378A.
[4] S. Akman, S. Akkoc, C. T. Zeyrek, M. T. Muhammed, and I. O. Ilhan, “Density functional modeling, and molecular docking with SARS-CoV-2 spike protein (Wuhan) and omicron S protein (variant) studies of new heterocyclic compounds including a pyrazoline nucleus,” Journal of Biomolecular Structure and Dynamics, 2023, doi: 10.1080/07391102.2023.2169765.
[5] A. Casimiro-Garcia et al., “Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5- dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist,” Journal of Medicinal Chemistry, vol. 57, no. 10, pp. 4273–4288, May 2014, doi: 10.1021/JM500206R.
[6] M. Mantzanidou, E. Pontiki, and D. Hadjipavlou-Litina, “Pyrazoles and pyrazolines as anti-inflammatory agents,” Molecules, vol. 26, no. 11, 2021, doi: 10.3390/molecules26113439.
[7] M. Payne, A. L. Bottomley, A. Och, A. P. Asmara, E. J. Harry, and A. T. Ung, “Synthesis and biological evaluation of 3,5-substituted pyrazoles as possible antibacterial agents,” Bioorganic & Medicinal Chemistry, vol. 48, p. 116401, Oct. 2021, doi: 10.1016/J.BMC.2021.116401.
[8] O. A. Nurkenov et al., “Synthesis, Structure, and Anti-Inflammatory Activity of Functionally Substituted Chalcones and Their Derivatives,” Russian Journal of General Chemistry, vol. 89, no. 7, pp. 1360–1367, 2019, doi: 10.1134/S1070363219070028.
[9] L. Kumar, K. Lal, A. Kumar, A. Paul, A. K.-J. of M. Structure, and undefined 2021, “Pyrazoline tethered 1, 2, 3-triazoles: Synthesis, antimicrobial evaluation and in silico studies,” Elsevier, Accessed: Jul. 20, 2023. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0022286021012849
[10] L. Kumar, K. Lal, P. Yadav, A. Kumar, A. P.-J. of M. Structure, and undefined 2020, “Synthesis, characterization, α-glucosidase inhibition and molecular modeling studies of some pyrazoline-1H-1, 2, 3-triazole hybrids,” Elsevier, Accessed: Jul. 20, 2023. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0022286020305780
[11] N. K. Rasal, R. Bhaskar Sonawane, and S. V. Jagtap, “Synthesis, Characterization, and Biological Study of 3‐Trifluoromethylpyrazole Tethered Chalcone‐Pyrrole and Pyrazoline‐Pyrrole Derivatives,” Wiley Online Library, vol. 18, no. 10, Oct. 2021, doi: 10.1002/cbdv.202100504.
[12] A. S. Nair et al., “Development of Halogenated Pyrazolines as Selective Monoamine Oxidase-B Inhibitors: Deciphering via Molecular Dynamics Approach,” Molecules 2021, Vol. 26, Page 3264, vol. 26, no. 11, p. 3264, May 2021, doi: 10.3390/MOLECULES26113264.
[13] A. Kumar, P. Kumar, C. Raju Shetty, J. Puthenveettil James, and H. Chandrashekhar Shetty, “Synthesis, antidiabetic evaluation and bioisosteric modification of quinoline incorporated 2-pyrazoline derivatives,” ijper.orgA Kumar, P Kumar, CR Shetty, JP James, HC ShettyIndian J. Pharm. Educ. Res, 2021•ijper.org, vol. 55, doi: 10.5530/ijper.55.2.96.
[14] P. J. Pharm Sci et al., “Synthesis, molecular docking and anti-diabetic studies of novel benzimidazole-pyrazoline hybrid molecules,” vol. 33, no. 2, pp. 847–854, 2020, doi: 10.36721/PJPS.2020.33.2.SUP.847-854.1.
[15] H. N. Akolkar et al., “Design, Synthesis and Biological Evaluation of Novel Furan & Thiophene Containing Pyrazolyl Pyrazolines as Antimalarial Agents,” Polycyclic Aromatic Compounds, vol. 42, no. 5, pp. 1959–1971, 2022, doi: 10.1080/10406638.2020.1821231.
[16] G. Çelik, T. Arslan, M. Şentürk, D. E.-A. der Pharmazie, and undefined 2020, “Synthesis and characterization of some new pyrazolines and their inhibitory potencies against carbonic anhydrases,” Wiley Online LibraryG Çelik, T Arslan, M Şentürk, D EkinciArchiv der Pharmazie, 2020•Wiley Online Library, vol. 353, no. 3, Mar. 2020, doi: 10.1002/ardp.201900292.
[17] E. Kamogawa and Y. Sueishi, “A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox,” Bioorganic and Medicinal Chemistry Letters, vol. 24, no. 5, pp. 1376–1379, 2014, doi: 10.1016/j.bmcl.2014.01.045.
[18] J. Alex, R. K. enzyme inhibition and medicinal chemistry, and undefined 2014, “4,5-Dihydro-1H-pyrazole: an indispensable scaffold,” Taylor & Francis, vol. 29, no. 3, pp. 427–442, 2014, doi: 10.3109/14756366.2013.795956.
[19] M. Goodarzi, W. Saeys, M. C. U. De Araujo, R. K. H. Galvão, and Y. Vander Heyden, “Binary classification of chalcone derivatives with LDA or KNN based on their antileishmanial activity and molecular descriptors selected using the Successive Projections Algorithm feature-selection technique,” European Journal of Pharmaceutical Sciences, vol. 51, no. 1, pp. 189–195, Jan. 2014, doi: 10.1016/J.EJPS.2013.09.019.
[20] B. Chen, Z. Zhu, M. Chen, W. Dong, and Z. Li, “Three-dimensional quantitative structure–activity relationship study on antioxidant capacity of curcumin analogues,” Journal of Molecular Structure, vol. 1061, no. 1, pp. 134–139, Mar. 2014, doi: 10.1016/J.MOLSTRUC.2013.12.083.
[21] Z. Y. Du et al., “Anti-proliferative, anti-inflammatory and antioxidant effects of curcumin analogue A2,” Archives of Pharmacal Research, vol. 36, no. 10, pp. 1204–1210, 2013, doi: 10.1007/s12272-013-0216-1.
[22] S. Bukhari, S. Franzblau, I. Jantan, and M. Jasamai, “Current Prospects of Synthetic Curcumin Analogs and Chalcone Derivatives Against Mycobacterium Tuberculosis,” Medicinal Chemistry, vol. 9, no. 7, pp. 897–903, Sep. 2013, doi: 10.2174/1573406411309070002.
[23] H. L. Qin et al., “Synthesis of α,β-Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells,” Journal of Medicinal Chemistry, vol. 59, no. 7, pp. 3549–3561, Apr. 2016, doi: 10.1021/ACS.JMEDCHEM.6B00276/SUPPL_FILE/JM6B00276_SI_002.CSV.
[24] A. Iraji, M. Saeedi, T. Rafiee-Sereshky, S. Mojtabavi, M. A. Faramarzi, and T. Akbarzadeh, “Ugi Adducts: Design and Synthesis of Natural-based α-glucosidase Inhibitors,” Letters in Organic Chemistry, vol. 19, no. 12, pp. 1084–1093, Apr. 2022, doi: 10.2174/1570178619666220401143634.
[25] J. L. Ou, Y. Mizushina, S. Y. Wang, D. Y. Chuang, M. Nadar, and W. L. Hsu, “Structure–activity relationship analysis of curcumin analogues on anti-influenza virus activity,” The FEBS Journal, vol. 280, no. 22, pp. 5829–5840, Nov. 2013, doi: 10.1111/FEBS.12503.
[26] M. Correia-Da-Silva et al., “Synthesis and Characterization of Curcumin-Chitosan Loaded Gold Nanoparticles by Oryctes rhinoceros’ Chitin for Cosmeceutical Application,” Molecules 2023, Vol. 28, Page 1799, vol. 28, no. 4, p. 1799, Feb. 2023, doi: 10.3390/MOLECULES28041799.
[27] S. Salomone et al., “Immunosuppressive Effects of Natural α,β-Unsaturated Carbonyl-Based Compounds, and Their Analogs and Derivatives, on Immune Cells: A Review,” Frontiers in Pharmacology | www.frontiersin.org, vol. 1, p. 22, 2017, doi: 10.3389/fphar.2017.00022.
[28] Z. P. HUO, X. C. FENG, Y. WANG, Y. T. TIAN, and F. QIU, “Sulfite as the substrate of C-sulfonate metabolism of α, β-unsaturated carbonyl containing andrographolide: analysis of sulfite in rats’ intestinal tract and the reaction kinetics of andrographolide with sulfite,” Chinese Journal of Natural Medicines, vol. 19, no. 9, pp. 706–712, Sep. 2021, doi: 10.1016/S1875-5364(21)60094-8.
[29] M. Grima, B. Michel, … M. B.-A. des M., and undefined 1990, “Mechanism of action of the diuretic effect of muzolimine,” europepmc.org, Accessed: Sep. 13, 2023. [Online]. Available: https://europepmc.org/article/med/2124457
[30] R. Surendra Kumar, I. A. Arif, A. Ahamed, and A. Idhayadhulla, “Anti-inflammatory and antimicrobial activities of novel pyrazole analogues,” Saudi Journal of Biological Sciences, vol. 23, no. 5, pp. 614–620, Sep. 2016, doi: 10.1016/J.SJBS.2015.07.005.
[31] S. A. O. Beebany, “Preparation and Identification of New 1,4-bis (5,3-substituted-2,3-dihydro-1H-pyrazole-1-yl) Buta-1,4-Dione Derivatives with Their Antibacterial Effect Evaluation,” 2023, doi: 10.22034/CHEMM.2023.365060.1614.
[32] C. Shekhar Yadav et al., “Recent advances in the synthesis of pyrazoline derivatives from chalcones as potent pharmacological agents: A comprehensive review,” Results in Chemistry, vol. 7, p. 101326, Jan. 2024, doi: 10.1016/J.RECHEM.2024.101326.
[33] I. Azad et al., “Phenanthridine derivatives as promising new anticancer agents: Synthesis, biological evaluation and binding studies,” Future Medicinal Chemistry, vol. 12, no. 8, pp. 709–739, Apr. 2020, doi: 10.4155/FMC-2019-0016.
[34] A. Kalusalingam, R. Kalirajan, S. Jubie, B. Gowramma, and B. Suresh, “Synthesis and biological evaluation of some Chalcone derivatives Synthesis and Biological evaluation of some heterocyclic derivatives of Chalcones,” International Journal of ChemTech Research, vol. 1, no. 1, pp. 27–34, Accessed: Mar. 21, 2024. [Online]. Available: https://www.researchgate.net/publication/309665347
[35] A. Ahmad, A. Husain, S. A. Khan, M. Mujeeb, and A. Bhandari, “Synthesis, antimicrobial and antitubercular activities of some novel pyrazoline derivatives Antimicrobial and antitubercular activities of novel pyrazoline derivatives,” Journal of Saudi Chemical Society, vol. 20, no. 5, pp. 577–584, 2016, doi: 10.1016/j.jscs.2014.12.004.
[36] Clinical and Laboratory Standards Institute (CLSI), “Reference method for broth dilution,” Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3th ed., vol. 28, no. 14, pp. 0–13, 2008, [Online]. Available: https://clsi.org/media/1461/m27a3_sample.pdf
[37] A. R. Pandey et al., “Antileishmanial evaluation of triazole-butenolide conjugates: design, synthesis, in vitro screening, SAR and in silico ADME predictions,” RSC Medicinal Chemistry, vol. 14, no. 6, pp. 1131–1142, 2023, doi: 10.1039/d2md00464j.
[38] I. Azad, M. Nasibullah, T. Khan, F. Hassan, and Y. Akhter, “Exploring the novel heterocyclic derivatives as lead molecules for design and development of potent anticancer agents,” Journal of Molecular Graphics and Modelling, vol. 81, pp. 211–228, May 2018, doi: 10.1016/J.JMGM.2018.02.013.
[39] A. Daina, O. Michielin, and V. Zoete, “SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules,” Scientific Reports 2017 7:1, vol. 7, no. 1, pp. 1–13, Mar. 2017, doi: 10.1038/srep42717.
[40] H. Yang et al., “admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties,” Bioinformatics (Oxford, England), vol. 35, no. 6, pp. 1067–1069, Mar. 2019, doi: 10.1093/BIOINFORMATICS/BTY707.
[41] H. Khan et al., “Structure based docking and biological evaluation towards exploring potential anti-cancerous and apoptotic activity of 6-Gingerol against human prostate carcinoma cells,” BMC Complementary Medicine and Therapies, vol. 24, no. 1, pp. 1–23, 2024, doi: 10.1186/s12906-023-04269-1.
Published
2024-10-11
How to Cite
Chandra Shekhar Yadav, Atul Krishna, Vijay Kumar Verma, Zaheeb Rashid Wani, Iqbal Azad, Abdul Rahman Khan, & Minaxi B. Lohani. (2024). Design, Synthesis and Characterization of 5-(2-Bromo-5-Fluorophenyl)-3-(1h-Pyrrol-2-Yl)-4,5-Dihydro-1h-Pyrazole as Antifungal Agent. Revista Electronica De Veterinaria, 25(1S), 1416 -1421. https://doi.org/10.69980/redvet.v25i1S.1189